Skip to main content
Log in

Monoamine Oxidase Inhibitors

An Update on Drug Interactions

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

After initial enthusiasm, the use of monoamine oxidase inhibitors (MAOIs) has been limited by the wide range of MAOI-drug and MAOI-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions. Despite their clinical benefits, this has led to a reduction in use of such medications.

Discovery of the 2 main subgroups of monoamine oxidase, types A and B, led to the synthesis of MAOIs selective for one or other of these isoenzymes. Consequently, selegiline (deprenyl), a selective MAO-B inhibitor, was developed for the treatment of idiopathic Parkinson’s disease. This drug is useful in the treatment of the early stages of the disease and later on as an adjunct to other drug therapies. Although the selective MAO-A inhibitor, clorgiline (clorgyline), was found to be effective in the treatment of depression, it still retained the potential to cause hypertensive reactions.

Recently, agents that are not only selective, but reversible in their inhibition of MAO-A (RIMAs) have been synthesised (e.g. moclobemide and toloxatone), and have proven antidepressant efficacy. Whilst they are less likely to induce hypertensive reactions with the concomitant administration of sympathomimetic drugs or with tyramine-rich foodstuffs, it still seems wise to advocate care in co-prescribing potentially interacting medications and to advise a degree of caution with regard to the dietary intake of foodstuffs likely to contain a high tyramine content. Although these newer drugs represent an advance in safety, their use has, as yet, only been established in the treatment of depression. RIMAs also retain a potential for adverse interaction with other drugs. Concomitant prescription of serotonin-enhancing drugs should only be undertaken with caution for patients on moclobemide, toloxatone or selegiline. Coprescription of sympathomimetic drugs should also be avoided with these newer MAOIs and patients should be advised against purchasing over-the-counter preparations that may contain sympathomimetic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kline NS. Monoamine oxidase inhibitors: an unfinished picaresque tale. In: Ayd FG, Blackwell B, editors. Discoveries in biological psychiatry. Philadelphia: Lippincott, 1970: 194–204

    Google Scholar 

  2. Zeller EA, Barsky J. In vivo inhibition of liver and brain MAO by 1-izonicotinile-2-izopropyle-3-hydrosine. Proc Soc Exp BiolMed 1952; 81: 459–61

    PubMed  CAS  Google Scholar 

  3. Johnston JP. Some observations on a new monoamine oxidase inhibitor in brain tissue. Biochem Pharmacol 1968; 17: 1285–97

    Article  PubMed  CAS  Google Scholar 

  4. Rederer P, Youdim MBH, Rausch WD, et al. On the mode of action of 1-deprenyl in the human central nervous system. J Neural Transm 1978; 43: 217–26

    Article  Google Scholar 

  5. MAOIs move up the menu. Drug Ther Bull 1989; 27(16): 63–4

    Google Scholar 

  6. Bass C, Kerwin R. The rediscovery of MAOIs. BMJ 1989; 298: 345–6

    Article  PubMed  CAS  Google Scholar 

  7. Shaw DM. A study of refractory cases of depressive illness and their response to combined anti-depressant treatment. Br J Psychiatry 1977; 130: 4–51

    Google Scholar 

  8. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl 1989; 6: 38–45

    PubMed  Google Scholar 

  9. Bazire S. Interactions with MAOIs. Pharm J 1986; 238: 417–9

    Google Scholar 

  10. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991; 11(1): 55–9

    Article  PubMed  CAS  Google Scholar 

  11. Sullivan E, Shulman KL. Diet monoamine oxidase inhibitors: a re-examination. Can J Psychiatry 1984; 29: 707–11

    PubMed  CAS  Google Scholar 

  12. Sternbach H. Serotonin syndrome. Am J Psychiatry 1991; 148: 705–13

    PubMed  CAS  Google Scholar 

  13. Pare CMD. The present status of MAOIs. Br J Psychiatry 1985; 146: 576–84

    Article  PubMed  CAS  Google Scholar 

  14. Tyrer P. Towards rational therapy with MAOIs. Br J Psychiatry 1976; 128: 354–60

    Article  PubMed  CAS  Google Scholar 

  15. Tollefson GD. MAOIs: a review. J Clin Psychiatry 1983; 44: 280–8

    PubMed  CAS  Google Scholar 

  16. Freeman H. Moclobemide. Lancet 1993; 342: 1528–32

    Article  PubMed  CAS  Google Scholar 

  17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  18. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983; Suppl. 95: 57–80

    Article  CAS  Google Scholar 

  19. Mann JJ, Aarons SF, Wilner PJ, et al. Controlled study of the anti-depressant efficacy and side-effects of 1-deprenyl. Arch Gen Psychiatry 1989; 46: 45–50

    Article  PubMed  CAS  Google Scholar 

  20. Sunderland E, Cohen RM, Malchan S, et al. High dose selegiline in treatment resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607–15

    Article  PubMed  CAS  Google Scholar 

  21. Lecrubier Y. Risk benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Saf 1994; 10(4): 292–300

    Article  PubMed  CAS  Google Scholar 

  22. Lipper S, Murphy DL, Slater S, et al. Comparative behavioural effects of clorgyline and pargyline in man: a preliminary investigation. Psychopharmacol 1979; 62(2): 123–8

    Article  CAS  Google Scholar 

  23. Lader MH, Sakalin G, Tansella M. Interaction between sympathomimetic amines and a new MAOI. Psychopharmacologia 1972; 18: 118–23

    Article  Google Scholar 

  24. Livingston MG. Interactions with selective MAOIs. Lancet 1995; 345: 533–4

    Article  PubMed  CAS  Google Scholar 

  25. ABPI data sheet compendium, 1995/96. London: Datapharma Publications Ltd, 1995: 334

  26. McGrath PJ, Stewart JW, Quicken F. A possible 1-deprenyl induced hypertensive reaction. J Clin Psychopharmacol 1989; 9(4): 310–1

    Article  PubMed  CAS  Google Scholar 

  27. ABPI data sheet compendium, 1995/96. London: Datapharma Publications Ltd, 1995: 1447–8

  28. Dictionnairie Vidal 1993. Paris: OVP Editions du Vidal, 1993: 673

  29. Provost JC, Funck-Brentano C, Rovei V, et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone — a new reversible monoamine oxidase A inhibitor and oral tyramine in healthy subjects. Clin Pharmacol Ther 1992; 52: 384–94

    Article  PubMed  CAS  Google Scholar 

  30. Da Prada M, Zurcher C, Wuthrich I, et al. On tyramine, food, beverages and the reversible MAO-A inhibitor, moclobem-ide. J Neural Transm 1988; 26: 31–56

    Google Scholar 

  31. Suchowersky O, DeVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35(6): 571–2

    PubMed  CAS  Google Scholar 

  32. Gilbar PJ, Brodribb TR, Downey N. Serotonin syndrome due to a moclobemide imipramine interaction. A previously unre-ported drug interaction? [abstract]. Aust J Hosp Pharm 1995; 25: 75

    Google Scholar 

  33. Spigset O, Mjorndal T. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993; 306: 248

    Article  PubMed  CAS  Google Scholar 

  34. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses [letter]. Lancet 1993; 342: 1419

    Article  PubMed  CAS  Google Scholar 

  35. DArcy PF. Life threatening interaction between pethidine and selegiline. Int Pharm J 1991; 5(3): 105–7

    Google Scholar 

  36. Zornberg GL, Vodkin JA, Cohen NM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246

    Article  PubMed  CAS  Google Scholar 

  37. Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 1994; 21: 259–61

    PubMed  CAS  Google Scholar 

  38. White K, Simpson G. Combined MAOI — tricyclic anti-depressant treatment a re-evaluation. J Clin Psychopharmacol 1981; 1: 264–82

    Article  PubMed  CAS  Google Scholar 

  39. Spiker DG, Pugh DP. Combining tricyclic and MAOI antidepressants. Arch Gen Psychiatry 1976; 33: 828–30

    Article  PubMed  CAS  Google Scholar 

  40. Ananth J, Luchins D. A review of combined tricyclic and MAOI therapy. Compr Psychiatry 1977; 18(3): 221–30

    Article  PubMed  CAS  Google Scholar 

  41. Vandel S, Bertschy G, Perault MC, et al. Minor and clinical non-significant interaction between toloxatone and amitriptyline. Eur J Clin Psychol 1993; 44, 97–9

    CAS  Google Scholar 

  42. Lefebvre H, Noblet C, Moore N, et al. Pseudophaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. J Clin Endocrinol. In press

  43. Lefebvre H, Richard R, Noblet C, et al. Life threatening pseudophaeochromocytoma after toloxatone terbutaline and phenylephrine. Lancet 1993; 341: 555–6

    Article  PubMed  CAS  Google Scholar 

  44. Montastruc JL, Chamontin D, Senard JM, et al. Pseudophaeochromocytoma in Parkinsonian patient treated with fluoxetine and selegiline [letter]. Lancet 1993; 341: 555

    Article  PubMed  CAS  Google Scholar 

  45. Schorelin N-P, Mayershon M, Hoevels B. Cimetidine alters the disposition kinetics of the monoamine oxidase inhibitor moclobemide. Clin Pharmacol Ther 1991; 49: 32–8

    Article  Google Scholar 

  46. Bennett WN, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983; 3(3): 155–93

    PubMed  CAS  Google Scholar 

  47. Takyi BE. Excretion of drugs in human milk. Am J Hosp Pharm 1970; 28: 317–26

    Google Scholar 

  48. Annanth J. Side effects in the neonate from psychotropic agents excreted through breast feeding. Am J Psychiatry 1978; 135: 801–5

    Google Scholar 

  49. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561–96

    Article  PubMed  CAS  Google Scholar 

  50. Preskorn SH. Recent pharmacologie advances in anti-depressant therapy for the elderly. Am J Med. 1993; 94(5A): 2S–12S

    PubMed  CAS  Google Scholar 

  51. Baunbacher G, Hanson MS. Abuse of monoamine oxidase inhibitors. Am J Drug Alcohol Abuse 1992; 18(4): 399–406

    Article  Google Scholar 

  52. Vartopoulous D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991; 158: 856–7

    Article  Google Scholar 

  53. Cassidy S, Henry J. Fatal toxicity of anti-depressant drugs in overdosage. BMJ 1987; 295: 1021–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Livingston, M.G., Livingston, H.M. Monoamine Oxidase Inhibitors. Drug-Safety 14, 219–227 (1996). https://doi.org/10.2165/00002018-199614040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199614040-00002

Keywords

Navigation